Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 2507 • 2016 ACR/ARHP Annual Meeting
Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
Min Kyung Chung¹, Seo Hwa Kim², Haneul Kim¹, Jung Hee Koh¹, Jennifer Lee³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) has been recommended for the first line therapy of rheumatoid arthritis (RA), either alone or in combination with other DMARDs such as…
Abstract Number: 2510 • 2016 ACR/ARHP Annual Meeting
Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases
Jesús Tornero Molina¹, Jaime Calvo², Francisco Javier Ballina-García³, María Ángeles Belmonte⁴, Francisco J. Blanco^5,6, Miguel Angel Caracuel-Ruiz⁷, Jordi Carbonell⁸, Hector Corominas⁹, Eugenio Chamizo Carmona¹⁰, C. Hidalgo-Calleja¹¹, Jose Andres Roman Ivorra¹², José Luis Marenco de la Fuente¹³, J.V. Moreno¹⁴, Santiago Muñoz Fernandez¹⁵, Joan Miquel Nolla¹⁶, Trinidad Perez Sandoval¹⁷, Raimon Sanmarti¹⁸, Pilar Trenor¹⁹, Claudia Urrego²⁰, Javier Vidal¹ and José Rosas²¹, ¹Rheumatology Unit, Hospital de Guadalajara, Guadalajara, Spain, ²Rheumatology Unit, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ³Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁴Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁵Osteoarticular and Aging Research Lab, INIBIC Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, ⁷Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸Rheumatology Unit, Hospital del Mar, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Rheumatology, Hospital de Mérida, Mérida, Spain, ¹¹University of Salamanca Hospital, Salamanca, Spain, ¹²Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ¹³Rheumatology, Hospital de Valme, Seville, Spain, ¹⁴Rheumatologist. Vall D’Hebron Hospital, Barcelona, Spain, ¹⁵Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ¹⁶Rheumatology, Bellvitge University Hospital, Barcelona, Spain, ¹⁷Rheumatology, Hospital de León, LEÓN, Spain, ¹⁸Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁹Rheumatology Unit, Hospital Clínico de Valencia, Valencia, Spain, ²⁰Hospital G. Segovia, Segovia, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain
Background/Purpose: To develop recommendations for the management of parenteral MTX in rheumatic diseases based on best evidence and experience. Methods: A group of 21 experts…
Abstract Number: 2516 • 2016 ACR/ARHP Annual Meeting
Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort
Carter Thorne¹, Mohammad Movahedi², Angela Cesta², Xiuying Li², Emmanouil Rampakakis³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Previous studies have shown differences in the effectiveness and survival of subcutaneous vs. oral methotrexate. Furthermore, concurrent methotrexate therapy has been shown to enhance…
Abstract Number: 2569 • 2016 ACR/ARHP Annual Meeting
Restoration of Decreased Lymphocyte Counts and the Shift to Th1 and Effector Memory CD8+T Cell Subsets Associate with Spontaneous Regression of Lympho-Proliferative Disorders Developed in RA Patients Treated with Methotrexate
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹, Koichi Amano², Michihide Tokuhira³ and Tsutomu Takeuchi¹, ¹Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ³Department of Hematology, Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose: Methods: Forty-three RA patients complicated with LPD were identified and 76 control patients were selected. Among the 43 LPD patients, 28 were regressive and…
Abstract Number: 3091 • 2016 ACR/ARHP Annual Meeting
Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
Cem Gabay¹, Jérôme Msihid², Nikki Daskalakis³, Neil Graham⁴, Anne Barbot⁵, Moshe Zilberstein³ and Anita Boyapati⁴, ¹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland, ²Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, NJ, France, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, France
Background/Purpose: Patients with RA develop bone and joint damage due to chronic inflammation that is mediated by a destructive synovial pannus.1 The pannus is composed…
Abstract Number: 22 • 2016 ACR/ARHP Annual Meeting
Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis
Ani John¹, Angela Witt Prehn², Hebatullah Tawfik², George W. Reed³ and Joel Kremer⁴, ¹School of Health Sciences, Walden University, Minneapolis, CA, ²School of Health Sciences, Walden University, Minneapolis, MN, ³Corrona, LLC, Southborough, MA, ⁴The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: NAFLD is a leading cause of chronic liver disorders, unrelated to significant alcohol use. RA and NAFLD have shared risk factors such as age,…
Abstract Number: 3149 • 2016 ACR/ARHP Annual Meeting
“Early Use of Subcutaneous MTX Monotherapy Vs. MTX Oral or Combination Therapy Significantly Delays Time to Initiating Biologics in Early RA
Stephanie Gottheil¹, J Carter Thorne², Orit Schieir³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, Diane Tin⁷, Cheryl Barnabe⁸, Glen Hazlewood⁸, Edward Keystone⁹, Vivian P. Bykerk¹⁰, Janet E. Pope¹¹, Susan J. Bartlett¹² and Canadian Early Arthritis Cohort, ¹University of Western Ontario, LONDON, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³McGill University, Montreal, ON, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Institute de Rheumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁹Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada
Background/Purpose: Optimal treatment for moderate-severe early rheumatoid arthritis involves using a methotrexate-based, treat-to-target strategy aiming for remission. Achieving remission without using biologics may be preferable…
Abstract Number: 2L • 2015 ACR/ARHP Annual Meeting
Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
Peter C. Taylor¹, Edward C. Keystone^2,3, D. van der Heijde⁴, Yoshiya Tanaka⁵, Taeko Ishii⁶, Kahaku Emoto⁶, Lili Yang⁶, Vipin Arora⁶, Carol L. Gaich⁶, Terence Rooney⁶, Douglas E. Schlichting⁶, William Macias⁶, Stephanie de Bono⁶ and Michael E. Weinblatt⁷, ¹Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Brigham and Women’s Hospital, Boston, MA
Background/Purpose: In phase 3 studies, baricitinib (bari) improved disease activity in patients (pts) with active RA and an inadequate response (IR) to conventional synthetic DMARDs1…
Abstract Number: 463 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents for RA in Patients with MTX-Associated Lymphoproliferative Disorders
Takayuki Katsuyama¹, Ken-ei Sada¹, Noriko Toyota-Tatebe², Katsue S. Watanabe¹, Toru Kiguchi³ and Jun Wada², ¹Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ²Department of Medicine and Clinical Science,, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ³Department of Internal Medicine, Chugoku Central Hospital, Fukuyama, Japan
Background/Purpose: Methotrexate (MTX) is known as an anchor drug for the treatment of rheumatoid arthritis (RA), and MTX-associated lymphoproliferative disorders (MTX-LPD) is of current interest.…
Abstract Number: 473 • 2015 ACR/ARHP Annual Meeting
Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis
Leena R Baghdadi^1,2,3, Richard J Woodman², E Michael Shanahan⁴ and Arduino A Mangoni³, ¹Department of Family and Community Medicine, King Saud University, Riyadh, Saudi Arabia, ²Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia, ³Department of Clinical Pharmacology, Flinders University, Adelaide, Australia, ⁴Department of Rheumatology, Flinders University, Adelaide, Australia
Background/Purpose: Methotrexate (MTX) use has been associated with reduced cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA). Although MTX has anti-inflammatory effects, there…
Abstract Number: 538 • 2015 ACR/ARHP Annual Meeting
Multidrug Resistant Lymphocytes of Patients with Rheumatoid Arthritis Are Predictive for DMARD and Glucocorticoid Treatment Response
Jan Piet van Hamburg¹, Sandra M.J. Paulissen², Nadine Davelaar¹, Mieke Hazes³ and Erik Lubberts¹, ¹Rheumatology and Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ²Room Nb-84, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: A large fraction of patients with RA does not respond to treatment with glucocorticoids (GCs) and disease-modifying anti-rheumatic drugs (DMARDs), or becomes resistant in…
Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab
Gerd Burmester¹, Gurjit S. Kaeley², Arthur Kavanaugh³, Cem Gabay⁴, Daryl MacCarter⁵, Peter Nash⁶, Tsutomu Takeuchi⁷, Anabela Cardoso⁸, Shufang Liu⁹, Hartmut Kupper¹⁰ and Jasmina Kalabic¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of Florida, Jacksonville, FL, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁶Department of Medicine, University of Queensland, Brisbane, Australia, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Torre Oriente, AbbVie, Lisboa, Portugal, ⁹Immunology Development, AbbVie, North Chicago, IL, ¹⁰AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…
Abstract Number: 577 • 2015 ACR/ARHP Annual Meeting
Use of Subcutaneous MTX Does Not Prolong the Use of Traditional DMARD in Multi-DMARD Regimens and Has Insignificant Differences in Liver Enzymes Abnormalities When Compared with Oral MTX in Patients with Rheumatoid Arthritis: A Veteran Affairs Administrative Database Study
Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA; Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Our previous analyses using the national administrative database from Veteran Health Administration showed that RA patient who were switched from oral to subcutaneous MTX…
Abstract Number: 1043 • 2015 ACR/ARHP Annual Meeting
Enhancing Comparative Effectiveness Research By Combining Observational and Randomized Trial Data to Personalize the Choice Between Methotrexate and Triple Therapy for Methotrexate-Naïve Patients with Early Rheumatoid Arthritis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, Gilles Boire⁴, Carol Hitchon⁵, Edward C. Keystone⁶, Boulos Haraoui⁷, J Carter Thorne⁸, Diane Tin⁹, Janet E. Pope¹⁰, Daming Lin¹¹, VP Bykerk¹² and CATCH investigators, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Institut de Rhumatologie, Montreal, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for comparing efficacy of treatments, but the results may be less generalizable to clinical practice…
Abstract Number: 1045 • 2015 ACR/ARHP Annual Meeting
Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results
Roy Fleischmann¹, Tsutomu Takeuchi², Douglas E. Schlichting³, William L. Macias³, Terence Rooney³, Sirel Gurbuz³, Ivaylo Stoykov³, Scott D. Beattie³, Wen-Ling Kuo³ and M Schiff⁴, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Keio University School of Medicine, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Colorado, Denver, CO
Background/Purpose: In 2 completed phase 3 studies, baricitinib (bari) improved disease activity with a satisfactory safety profile in patients (pts) with moderately-to-severely active RA who…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].